Posted by Michael Wonder on 27 Sep 2022
Ayala Pharmaceuticals announces fast track designation granted by US FDA for AL102 in progressing desmoid tumours
27 September 202 - Ayala Pharmaceuticals today announced that the US FDA has granted fast track designation for AL102 for the treatment of progressing desmoid tumours.
AL102 is a potent, selective, oral gamma secretase inhibitor.
